These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32059178)

  • 1. Targeting glioma-initiating cells via the tyrosine metabolic pathway.
    Yamashita D; Bernstock JD; Elsayed G; Sadahiro H; Mohyeldin A; Chagoya G; Ilyas A; Mooney J; Estevez-Ordonez D; Yamaguchi S; Flanary VL; Hackney JR; Bhat KP; Kornblum HI; Zamboni N; Kim SH; Chiocca EA; Nakano I
    J Neurosurg; 2020 Feb; 134(3):721-732. PubMed ID: 32059178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
    Petővári G; Dankó T; Krencz I; Hujber Z; Rajnai H; Vetlényi E; Raffay R; Pápay J; Jeney A; Sebestyén A
    Pathol Oncol Res; 2020 Jan; 26(1):23-33. PubMed ID: 31187466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal transition and increased therapy resistance of glioblastoma cells is related to astrocyte reactivity.
    Niklasson M; Bergström T; Jarvius M; Sundström A; Nyberg F; Haglund C; Larsson R; Westermark B; Segerman B; Segerman A
    J Pathol; 2019 Nov; 249(3):295-307. PubMed ID: 31298733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells.
    López-Valero I; Dávila D; González-Martínez J; Salvador-Tormo N; Lorente M; Saiz-Ladera C; Torres S; Gabicagogeascoa E; Hernández-Tiedra S; García-Taboada E; Mendiburu-Eliçabe M; Rodríguez-Fornés F; Sánchez-Domínguez R; Segovia JC; Sánchez-Gómez P; Matheu A; Sepúlveda JM; Velasco G
    Theranostics; 2020; 10(11):5120-5136. PubMed ID: 32308772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase Eph receptor A6 sensitizes glioma-initiating cells towards bone morphogenetic protein-induced apoptosis.
    Raja E; Morikawa M; Nishida J; Tanabe R; Takahashi K; Seeherman HJ; Saito N; Todo T; Miyazono K
    Cancer Sci; 2019 Nov; 110(11):3486-3496. PubMed ID: 31483918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
    Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M
    Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
    Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
    Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.
    Fu J; Koul D; Yao J; Wang S; Yuan Y; Colman H; Sulman EP; Lang FF; Yung WK
    Cancer Res; 2013 May; 73(10):3062-74. PubMed ID: 23492364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
    Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
    Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
    Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
    Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.
    Zhao H; Heimberger AB; Lu Z; Wu X; Hodges TR; Song R; Shen J
    Oncotarget; 2016 Apr; 7(15):20486-95. PubMed ID: 26967252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACTC1 as an invasion and prognosis marker in glioma.
    Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
    J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.
    Liu M; Lin Y; Zhang XC; Tan YH; Yao YL; Tan J; Zhang X; Cui YH; Liu X; Wang Y; Bian XW
    Lab Invest; 2017 Nov; 97(11):1354-1363. PubMed ID: 28759011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of tibolone on the human primary glioblastoma multiforme cell culture and the rat C6 glioma model.
    Altinoz MA; Albayrak SB; Karasu A; Sabanci PA; Imer M; Bilir A
    Neurol Res; 2009 Nov; 31(9):923-7. PubMed ID: 19531283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.